Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Muscular dystrophy – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global muscular dystrophy market. The report identifies the key trends shaping and driving the global muscular dystrophy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global muscular dystrophy sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The Scope of the report includes:
- Annualized global muscular dystrophy revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global muscular dystrophy market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with muscular dystrophy.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global muscular dystrophy market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global muscular dystrophy market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global muscular dystrophy market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 GLOBAL MUSCULAR DYSTROPHY: MARKET CHARACTERIZATION

2.1 Overview
2.2 Muscular Dystrophy Market Size
2.3 Muscular Dystrophy Market Forecast and CAGR
2.4 Drivers and Barriers for the Muscular Dystrophy Market
  2.4.1 Drivers for the Muscular Dystrophy Market
  2.4.2 Barriers for the Muscular Dystrophy Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 GLOBAL MUSCULAR DYSTROPHY MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Muscular dystrophy Market
  3.3.1 Cosrticosteriods
  3.3.2 Prednisone
  3.3.3 Deflazacort
3.4 Key Takeaway

4 GLOBAL MUSCULAR DYSTROPHY MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
4.3 Muscular Dystrophy Market – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
  4.4.1 Catena/Sovrima (Idebenone)
  4.4.2 Ataluren (PTC124)
  4.4.3 IPlex(TM) (Mecasermin Rinfabate)
4.5 Muscular Dystrophy Market – Clinical Pipeline by Mechanism of Action
  4.5.1 Muscular Dystrophy – Phase III Clinical Pipeline
  4.5.2 Muscular Dystrophy – Phase II Clinical Pipeline
  4.5.3 Muscular Dystrophy – Phase I Clinical Pipeline
  4.5.4 Muscular Dystrophy – Preclinical Pipeline

4.5.5 MUSCULAR DYSTROPHY – LIST OF TERMINATED CLINICAL TRIALS

4.6 Key Takeaway

5 GLOBAL MUSCULAR DYSTROPHY MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION


6 GLOBAL MUSCULAR DYSTROPHY SYNDROME MARKET: FUTURE PLAYERS

6.1 Introduction
6.2 PTC Therapeutics, Inc
  6.2.1 Company Overview
  6.2.2 Business Description
6.3 Genzyme Corporation
  6.3.1 Company Overview
  6.3.2 Business Description
6.4 Santhera Pharmaceuticals AG
  6.4.1 Company Overview
  6.4.2 Business Description
6.5 Takeda Pharmaceuticals
  6.5.1 Overview
  6.5.2 Business Description
6.6 Avi Biopharma
  6.6.1 Company Overview
  6.6.2 Business Description
6.7 Insmed Incorporated
  6.7.1 Company Overview
  6.7.2 Business Description

7 MUSCULAR DYSTROPHY MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer

LIST OF TABLES

Table 1: Muscular Dystrophy, Global, Historical Revenue ($m), 2001-2009
Table 2: Muscular Dystrophy, Global, Forecasted Reveune ($m), 2009-2016
Table 3: Major Marketed Products Comparison in Muscular Dystrophy Market, 2010
Table 4: Muscular Dystrophy Syndrome – Most Promising Drugs Under Clinical Development, 2010
Table 5: Muscular Dystrophy – Phase III Clinical Pipeline, 2010
Table 6 Muscular Dystrophy– Phase II Clinical Pipeline, 2010
Table 7 Muscular Dystrophy – Phase I Clinical Pipeline, 2010
Table 8: Muscular Dystrophy– Preclinical Pipeline, 2010
Table 9: Muscular Dystrophy – List Of Terminated Clinical Trials, 2010
Table 10: PTC Therapeutics – Muscular Dystrophy Pipeline Product Portfolio, 2010
Table 11: Genzyme Corporation – Muscular Dystrophy Pipeline Product Portfolio, 2010
Table 12: Santhera Pharmaceuticals - Muscular Dystrophy Pipeline Product Portfolio, 2010
Table 13: Takeda Pharmaceuticals - Muscular Dystrophy Pipeline Product Portfolio, 2010
Table 14: Avi Biopharma - Muscular Dystrophy Pipeline Product Portfolio, 2010
Table 15: Insmed Incorporated - Muscular Dystrophy Pipeline Product Portfolio, 2010

LIST OF FIGURES

Figure 1: Muscular Dystrophy, Global, Historical Revenue ($m), 2001-2009
Figure 2: Muscular Dystrophy, Global, Forecasted Revenue ($m), 2009-2016
Figure 3: Opportunity and Unmet Need in the Muscular Dystrophy Market, 2010
Figure 4: Strategic Competitor Assessment, 2010
Figure 5: Pipeline Products by Phase of Development, 2010
Figure 6: Technology Trends Analytics Frame Work, 2010
Figure 7: Technology Trends Analytics Frame Work – Description, 2010
Figure 8: Muscular Dystrophy Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 9: Muscular Dystrophy Market – Clinical Pipeline by Phase of Development, 2010
Figure 10: Implications for Future Market Competition in the Muscular Dystrophy Market, 2010
Figure 11: Muscular Dystrophy Market – Clinical Pipeline by Company, 2010
Figure 12: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model

COMPANIES MENTIONED

PTC Therapeutics, Inc
Genzyme Corporation
Santhera Pharmaceuticals AG
Takeda Pharmaceuticals
Avi Biopharma
Insmed Incorporated Skip to top